Why Electrome Fits the CMS ACCESS Model

The CMS access framework asks programs to do three things at once. Deliver evidence backed care. Capture longitudinal data on adherence and outcomes. Reach patient populations equitably, including patients who have historically had less access to specialty pain care. The Electrome platform was designed around exactly that triad, not as a response to the framework, but because the same triad is what serious bioelectric care requires regardless of what any agency calls it.

Evidence backed therapy

The therapy itself, FDA cleared pulsed shortwave therapy delivered through a wearable device, sits on a peer reviewed evidence base for musculoskeletal pain and edema. The platform does not stretch indications. The clinical materials describe the therapy in the language the FDA cleared. That precision is part of what allows the platform to be operated inside payer programs without raising the kind of compliance flags that less disciplined claims would.

Longitudinal data

Every PAINKILLER session, with patient consent, contributes a small structured record. Use time, intensity, body region, patient reported outcome. None of those records are remarkable individually. In aggregate they are the longitudinal dataset that RTM workflows expect, and they are the documentation that payer audits depend on. The platform's data layer is purpose built to produce that record without imposing extra work on the patient or the clinician.

Equitable access

The third leg of the framework is the one that platforms most often underdeliver on. Equitable access requires reach into patient populations that traditional specialty care has not always reached well. The Electrome platform was built with multiple entry points specifically for this reason. Retailers reach patients who do not enter the system through a specialist. Provider programs reach patients inside a clinical relationship. Affiliate creators reach patients inside the communities those creators are part of. A platform that reads all three channels into one data backbone is one of the few structures that can credibly claim equitable reach without losing the rigor of the clinical surface.

What this looks like in a real program

A real program inside the framework looks like this. A patient enters through any of the three channels. The platform sets up the wearable, the protocol, and the check in cadence. The clinician, if there is one in the loop, sees the stream in the workspace. RTM documentation is generated as a byproduct of the patient's actual usage. Outcomes are captured continuously. Reports are available for payer review on demand. The patient has a single experience. The infrastructure handles the rest.

What this does not look like

It does not look like a marketing program with bioelectric language draped over it. It does not look like a claims expansion exercise. It does not look like an attempt to fit a device into a code that was not designed for it. The framework rewards programs that fit cleanly into the structure that already exists, and the Electrome platform's deliberate self limitation, the platform does what the FDA cleared the device to do and stops there, is what makes the fit clean.

The longer view

The CMS access framework is not the only way the federal system can encourage this kind of program, and it likely will not be the last. The point is not that any one framework defines the platform. The point is that the platform was built in a way that lines up naturally with how serious payer and government programs evaluate non pharmacologic pain care. That alignment is the reason the platform can scale inside those programs without rebuilding for each one.